The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Recombinant Insulin Analogue Market Research Report 2025
Synopsis
Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.
Highlights
The global Recombinant Insulin Analogue market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Recombinant Insulin Analogue include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Recombinant Insulin Analogue in Type 1 Diabetes is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Quick-Acting, which accounted for % of the global market of Recombinant Insulin Analogue in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Insulin Analogue, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Insulin Analogue.
The Recombinant Insulin Analogue market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Recombinant Insulin Analogue market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Insulin Analogue manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd
Product Type Insights
Global markets are presented by Recombinant Insulin Analogue type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Recombinant Insulin Analogue are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Recombinant Insulin Analogue segment by Type
Quick-Acting
Medium Effect
Long-Lasting
Super Long-Acting
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Recombinant Insulin Analogue market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Recombinant Insulin Analogue market.
Recombinant Insulin Analogue segment by Application
Type 1 Diabetes
Type 2 Diabetes
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant Insulin Analogue market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Insulin Analogue market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Recombinant Insulin Analogue and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Recombinant Insulin Analogue industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Insulin Analogue.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Insulin Analogue manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Insulin Analogue in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.
Highlights
The global Recombinant Insulin Analogue market is projected to reach US$ million by 2028 from an estimated US$ million in 2022, at a CAGR of % during 2023 and 2028.
North American market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
Asia-Pacific market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
The major global manufacturers of Recombinant Insulin Analogue include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc. In 2021, the world's top three vendors accounted for approximately % of the revenue.
The global market for Recombinant Insulin Analogue in Type 1 Diabetes is estimated to increase from $ million in 2022 to $ million by 2028, at a CAGR of % during the forecast period of 2022 through 2028.
Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Quick-Acting, which accounted for % of the global market of Recombinant Insulin Analogue in 2021, is expected to reach million US$ by 2028, growing at a revised CAGR of % from 2022 to 2028.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Recombinant Insulin Analogue, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant Insulin Analogue.
The Recombinant Insulin Analogue market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Recombinant Insulin Analogue market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Recombinant Insulin Analogue manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd
Product Type Insights
Global markets are presented by Recombinant Insulin Analogue type, along with growth forecasts through 2028. Estimates on sales and revenue are based on the price in the supply chain at which the Recombinant Insulin Analogue are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2017-2022) and forecast period (2023-2028).
Recombinant Insulin Analogue segment by Type
Quick-Acting
Medium Effect
Long-Lasting
Super Long-Acting
Application Insights
This report has provided the market size (sales and revenue data) by application, during the historical period (2017-2022) and forecast period (2023-2028).
This report also outlines the market trends of each segment and consumer behaviors impacting the Recombinant Insulin Analogue market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Recombinant Insulin Analogue market.
Recombinant Insulin Analogue segment by Application
Type 1 Diabetes
Type 2 Diabetes
Regional Outlook
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028.
The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2021 because of the base year, with estimates for 2022 and forecast revenue for 2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant Insulin Analogue market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Reasons to Buy This Report
This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Insulin Analogue market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Recombinant Insulin Analogue and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Recombinant Insulin Analogue industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Insulin Analogue.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Recombinant Insulin Analogue manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Recombinant Insulin Analogue in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Analysis of sales channel, distributors and customers
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: sales and revenue forecast, global and regional, by Type and by Application. It provides a quantitative analysis of the market size and development potential of each market segment in the next six years.
Chapter 11: The main points and conclusions of the report.
Index1 Recombinant Insulin Analogue Market Overview
1.1 Product Overview and Scope of Recombinant Insulin Analogue
1.2 Recombinant Insulin Analogue Segment by Type
1.2.1 Global Recombinant Insulin Analogue Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Quick-Acting
1.2.3 Medium Effect
1.2.4 Long-Lasting
1.2.5 Super Long-Acting
1.3 Recombinant Insulin Analogue Segment by Application
1.3.1 Global Recombinant Insulin Analogue Sales Comparison by Application: (2022-2028)
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Global Recombinant Insulin Analogue Market Size Estimates and Forecasts
1.4.1 Global Recombinant Insulin Analogue Revenue 2017-2028
1.4.2 Global Recombinant Insulin Analogue Sales 2017-2028
1.4.3 Recombinant Insulin Analogue Market Size by Region: 2017 Versus 2021 Versus 2028
2 Recombinant Insulin Analogue Market Competition by Manufacturers
2.1 Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2017-2022)
2.2 Global Recombinant Insulin Analogue Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Recombinant Insulin Analogue Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Recombinant Insulin Analogue Manufacturing Sites, Area Served, Product Type
2.5 Recombinant Insulin Analogue Market Competitive Situation and Trends
2.5.1 Recombinant Insulin Analogue Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Recombinant Insulin Analogue Players Market Share by Revenue
2.5.3 Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Insulin Analogue Retrospective Market Scenario by Region
3.1 Global Recombinant Insulin Analogue Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Recombinant Insulin Analogue Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Recombinant Insulin Analogue Market Facts & Figures by Country
3.3.1 North America Recombinant Insulin Analogue Sales by Country
3.3.2 North America Recombinant Insulin Analogue Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Recombinant Insulin Analogue Market Facts & Figures by Country
3.4.1 Europe Recombinant Insulin Analogue Sales by Country
3.4.2 Europe Recombinant Insulin Analogue Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Recombinant Insulin Analogue Market Facts & Figures by Region
3.5.1 Asia Pacific Recombinant Insulin Analogue Sales by Region
3.5.2 Asia Pacific Recombinant Insulin Analogue Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Recombinant Insulin Analogue Market Facts & Figures by Country
3.6.1 Latin America Recombinant Insulin Analogue Sales by Country
3.6.2 Latin America Recombinant Insulin Analogue Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Recombinant Insulin Analogue Market Facts & Figures by Country
3.7.1 Middle East and Africa Recombinant Insulin Analogue Sales by Country
3.7.2 Middle East and Africa Recombinant Insulin Analogue Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Recombinant Insulin Analogue Historic Market Analysis by Type
4.1 Global Recombinant Insulin Analogue Sales Market Share by Type (2017-2022)
4.2 Global Recombinant Insulin Analogue Revenue Market Share by Type (2017-2022)
4.3 Global Recombinant Insulin Analogue Price by Type (2017-2022)
5 Global Recombinant Insulin Analogue Historic Market Analysis by Application
5.1 Global Recombinant Insulin Analogue Sales Market Share by Application (2017-2022)
5.2 Global Recombinant Insulin Analogue Revenue Market Share by Application (2017-2022)
5.3 Global Recombinant Insulin Analogue Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Novo Nordisk A/S
6.1.1 Novo Nordisk A/S Corporation Information
6.1.2 Novo Nordisk A/S Description and Business Overview
6.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Product Portfolio
6.1.5 Novo Nordisk A/S Recent Developments/Updates
6.2 Eli Lilly and Company
6.2.1 Eli Lilly and Company Corporation Information
6.2.2 Eli Lilly and Company Description and Business Overview
6.2.3 Eli Lilly and Company Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Eli Lilly and Company Recombinant Insulin Analogue Product Portfolio
6.2.5 Eli Lilly and Company Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2017-2022)
6.3.4 Sanofi Recombinant Insulin Analogue Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Gan & Lee Pharmaceuticals Co., Ltd
6.4.1 Gan & Lee Pharmaceuticals Co., Ltd Corporation Information
6.4.2 Gan & Lee Pharmaceuticals Co., Ltd Description and Business Overview
6.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Portfolio
6.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates
6.5 The United Laboratories International Holdings Limited
6.5.1 The United Laboratories International Holdings Limited Corporation Information
6.5.2 The United Laboratories International Holdings Limited Description and Business Overview
6.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2017-2022)
6.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Portfolio
6.5.5 The United Laboratories International Holdings Limited Recent Developments/Updates
6.6 Tonghua Dongbao Pharmaceutical Co., Ltd
6.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information
6.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Description and Business Overview
6.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Portfolio
6.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments/Updates
7 Recombinant Insulin Analogue Manufacturing Cost Analysis
7.1 Recombinant Insulin Analogue Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Recombinant Insulin Analogue
7.4 Recombinant Insulin Analogue Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Recombinant Insulin Analogue Distributors List
8.3 Recombinant Insulin Analogue Customers
9 Recombinant Insulin Analogue Market Dynamics
9.1 Recombinant Insulin Analogue Industry Trends
9.2 Recombinant Insulin Analogue Market Drivers
9.3 Recombinant Insulin Analogue Market Challenges
9.4 Recombinant Insulin Analogue Market Restraints
10 Global Market Forecast
10.1 Recombinant Insulin Analogue Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Recombinant Insulin Analogue by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Recombinant Insulin Analogue by Type (2023-2028)
10.2 Recombinant Insulin Analogue Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Recombinant Insulin Analogue by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Recombinant Insulin Analogue by Application (2023-2028)
10.3 Recombinant Insulin Analogue Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Recombinant Insulin Analogue by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Recombinant Insulin Analogue by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Recombinant Insulin Analogue Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Recombinant Insulin Analogue Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Recombinant Insulin Analogue Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Recombinant Insulin Analogue Market Competitive Situation by Manufacturers in 2021
Table 5. Global Recombinant Insulin Analogue Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Recombinant Insulin Analogue Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Recombinant Insulin Analogue Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Recombinant Insulin Analogue Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Recombinant Insulin Analogue Manufacturing Sites and Area Served
Table 11. Manufacturers Recombinant Insulin Analogue Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Recombinant Insulin Analogue by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Insulin Analogue as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Recombinant Insulin Analogue Sales by Region (2017-2022) & (K Units)
Table 16. Global Recombinant Insulin Analogue Sales Market Share by Region (2017-2022)
Table 17. Global Recombinant Insulin Analogue Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Recombinant Insulin Analogue Revenue Market Share by Region (2017-2022)
Table 19. North America Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 20. North America Recombinant Insulin Analogue Sales Market Share by Country (2017-2022)
Table 21. North America Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Recombinant Insulin Analogue Revenue Market Share by Country (2017-2022)
Table 23. Europe Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 24. Europe Recombinant Insulin Analogue Sales Market Share by Country (2017-2022)
Table 25. Europe Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Recombinant Insulin Analogue Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Recombinant Insulin Analogue Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Recombinant Insulin Analogue Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Recombinant Insulin Analogue Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Recombinant Insulin Analogue Revenue Market Share by Region (2017-2022)
Table 31. Latin America Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Recombinant Insulin Analogue Sales Market Share by Country (2017-2022)
Table 33. Latin America Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Recombinant Insulin Analogue Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Recombinant Insulin Analogue Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Recombinant Insulin Analogue Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Recombinant Insulin Analogue Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Recombinant Insulin Analogue Revenue Market Share by Country (2017-2022)
Table 39. Global Recombinant Insulin Analogue Sales by Type (2017-2022) & (K Units)
Table 40. Global Recombinant Insulin Analogue Sales Market Share by Type (2017-2022)
Table 41. Global Recombinant Insulin Analogue Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Recombinant Insulin Analogue Revenue Share by Type (2017-2022)
Table 43. Global Recombinant Insulin Analogue Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Recombinant Insulin Analogue Sales (K Units) by Application (2017-2022)
Table 45. Global Recombinant Insulin Analogue Sales Market Share by Application (2017-2022)
Table 46. Global Recombinant Insulin Analogue Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Recombinant Insulin Analogue Revenue Share by Application (2017-2022)
Table 48. Global Recombinant Insulin Analogue Price by Application (2017-2022) & (US$/Unit)
Table 49. Novo Nordisk A/S Corporation Information
Table 50. Novo Nordisk A/S Description and Business Overview
Table 51. Novo Nordisk A/S Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Novo Nordisk A/S Recombinant Insulin Analogue Product
Table 53. Novo Nordisk A/S Recent Developments/Updates
Table 54. Eli Lilly and Company Corporation Information
Table 55. Eli Lilly and Company Description and Business Overview
Table 56. Eli Lilly and Company Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Eli Lilly and Company Recombinant Insulin Analogue Product
Table 58. Eli Lilly and Company Recent Developments/Updates
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Business Overview
Table 61. Sanofi Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. Sanofi Recombinant Insulin Analogue Product
Table 63. Sanofi Recent Developments/Updates
Table 64. Gan & Lee Pharmaceuticals Co., Ltd Corporation Information
Table 65. Gan & Lee Pharmaceuticals Co., Ltd Description and Business Overview
Table 66. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product
Table 68. Gan & Lee Pharmaceuticals Co., Ltd Recent Developments/Updates
Table 69. The United Laboratories International Holdings Limited Corporation Information
Table 70. The United Laboratories International Holdings Limited Description and Business Overview
Table 71. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product
Table 73. The United Laboratories International Holdings Limited Recent Developments/Updates
Table 74. Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information
Table 75. Tonghua Dongbao Pharmaceutical Co., Ltd Description and Business Overview
Table 76. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product
Table 78. Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments/Updates
Table 79. Production Base and Market Concentration Rate of Raw Material
Table 80. Key Suppliers of Raw Materials
Table 81. Recombinant Insulin Analogue Distributors List
Table 82. Recombinant Insulin Analogue Customers List
Table 83. Recombinant Insulin Analogue Market Trends
Table 84. Recombinant Insulin Analogue Market Drivers
Table 85. Recombinant Insulin Analogue Market Challenges
Table 86. Recombinant Insulin Analogue Market Restraints
Table 87. Global Recombinant Insulin Analogue Sales Forecast by Type (2023-2028) & (K Units)
Table 88. Global Recombinant Insulin Analogue Sales Market Share Forecast by Type (2023-2028)
Table 89. Global Recombinant Insulin Analogue Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 90. Global Recombinant Insulin Analogue Revenue Market Share Forecast by Type (2023-2028)
Table 91. Global Recombinant Insulin Analogue Sales Forecast by Application (2023-2028) & (K Units)
Table 92. Global Recombinant Insulin Analogue Sales Market Share Forecast by Application (2023-2028)
Table 93. Global Recombinant Insulin Analogue Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 94. Global Recombinant Insulin Analogue Revenue Market Share Forecast by Application (2023-2028)
Table 95. Global Recombinant Insulin Analogue Sales Forecast by Region (2023-2028) & (K Units)
Table 96. Global Recombinant Insulin Analogue Sales Market Share Forecast by Region (2023-2028)
Table 97. Global Recombinant Insulin Analogue Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 98. Global Recombinant Insulin Analogue Revenue Market Share Forecast by Region (2023-2028)
Table 99. Research Programs/Design for This Report
Table 100. Key Data Information from Secondary Sources
Table 101. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Insulin Analogue
Figure 2. Global Recombinant Insulin Analogue Market Share by Type in 2021 & 2028
Figure 3. Quick-Acting Product Picture
Figure 4. Medium Effect Product Picture
Figure 5. Long-Lasting Product Picture
Figure 6. Super Long-Acting Product Picture
Figure 7. Global Recombinant Insulin Analogue Market Share by Application in 2021 & 2028
Figure 8. Type 1 Diabetes
Figure 9. Type 2 Diabetes
Figure 10. Global Recombinant Insulin Analogue Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Recombinant Insulin Analogue Market Size (2017-2028) & (US$ Million)
Figure 12. Global Recombinant Insulin Analogue Sales (2017-2028) & (K Units)
Figure 13. Recombinant Insulin Analogue Sales Share by Manufacturers in 2021
Figure 14. Global Recombinant Insulin Analogue Revenue Share by Manufacturers in 2021
Figure 15. The Global 5 and 10 Largest Recombinant Insulin Analogue Players: Market Share by Revenue in 2021
Figure 16. Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 17. Global Recombinant Insulin Analogue Sales Market Share by Region (2017-2022)
Figure 18. Global Recombinant Insulin Analogue Sales Market Share by Region in 2021
Figure 19. Global Recombinant Insulin Analogue Revenue Market Share by Region (2017-2022)
Figure 20. Global Recombinant Insulin Analogue Revenue Market Share by Region in 2021
Figure 21. United States Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 22. Canada Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 23. Germany Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 24. France Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. U.K. Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Italy Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. Russia Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. China Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Japan Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. South Korea Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. India Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Australia Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. China Taiwan Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. Indonesia Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Thailand Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. Malaysia Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Mexico Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Brazil Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Argentina Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Colombia Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Turkey Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Saudi Arabia Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. UAE Recombinant Insulin Analogue Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Sales Market Share of Recombinant Insulin Analogue by Type (2017-2022)
Figure 45. Manufacturing Cost Structure of Recombinant Insulin Analogue
Figure 46. Manufacturing Process Analysis of Recombinant Insulin Analogue
Figure 47. Recombinant Insulin Analogue Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
